Budesonid ( DrugBank: - )
1 disease
| 告示番号 | 疾患名(ページ内リンク) | 臨床試験数 | 
|---|---|---|
| 95 | 自己免疫性肝炎 | 3 | 
95. 自己免疫性肝炎
臨床試験数 : 52 / 薬物数 : 68 - (DrugBank : 28) / 標的遺伝子数 : 19 - 標的パスウェイ数 : 112
| No. | TrialID | Date_ enrollment  | Date_ registration  | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor  | Secondary_ sponsor  | Recruitment_ Status  | Inclusion_ agemin  | Inclusion_ agemax  | Inclusion_ gender  | Target_ size  | Phase | Countries | 
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2018-003381-14-SE (EUCTR)  | 19/02/2020 | 11/12/2019 | Budesonide compared to prednisolone for the treatment of autoimmunehepatitis - A prospective randomized multicenter study | Budesonide versus Prednisolone as Primary Treatment for AutoimmuneHepatitis: An Open-label, Randomized, Prospective Multicenter 12-monthClinical Trial Evaluating Effect and Side-Effects. - AIHBUDPRED | Autoimmune hepatitis;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Prednisolon Product Name: Prednisolon Trade Name: Budesonid Product Name: Various  | Umeå University Hospital | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes  | 150 | Phase 4 | Sweden | ||
| 2 | NCT00587119 (ClinicalTrials.gov)  | December 2007 | 21/12/2007 | Oral Budesonide in the Treatment of Patients With Primary Biliary Cirrhosis and Overlap Features of Autoimmune Hepatitis | Open-Label Pilot Study Evaluating Oral Budesonide in the Treatment of Patients With Primary Biliary Cirrhosis and Overlap Features of Autoimmune Hepatitis. | Primary Biliary Cirrhosis;Autoimmune Hepatitis | Drug: Budesonide | Mayo Clinic | NULL | Withdrawn | 21 Years | 75 Years | Both | 0 | N/A | United States | 
| 3 | NCT00838214 (ClinicalTrials.gov)  | March 2001 | 5/2/2009 | Budesonide 3x3mg/d Versus Prednisone in Active Autoimmune Hepatitis | Efficacy and Safety of Budesonide Capsules (3x3mg/d)Versus Prednisone in Patients With a Diagnose of Active Autoimmune Hepatitis. A Double-blind, Randomized, Active-controlled, Multicentre Study | Autoimmune Hepatitis | Drug: budesonide;Drug: prednisone | Dr. Falk Pharma GmbH | NULL | Completed | 10 Years | 70 Years | All | 208 | Phase 2/Phase 3 | Germany |